Epidemiology of Intracranial Gliomas

Ostrom, Quinn T.; Gittleman, Haley; Stetson, Lindsay; Virk, Selene; Barnholtz‐Sloan, Jill S.

doi:10.1159/000464374

Cited by 90 publications

(61 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Glioma is one of the most common brain tumors, which accounts for almost 80% of brain cancers and is associated with a high mortality, including astrocytoma, ependymoma, oligodendroglioma, glioblastoma, and medulloblastoma . Glioma accounts for 31% of malignant brain and 81% of central nervous system (CNS) tumors diagnosed in the United States, respectively . In China, 1 016 000 people were diagnosed with brain and CNS cancer .…”

Section: Introductionmentioning

confidence: 99%

“…1 Glioma accounts for 31% of malignant brain and 81% of central nervous system (CNS) tumors diagnosed in the United States, respectively. 2 In China, 1 016 000 people were diagnosed with brain and CNS cancer. 3 Despite advances in surgical resection, chemotherapy, and radiotherapy, the prognosis of patients with glioma remains unfavorable, even with 15 months median survival in highgrade glioma.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of four lncRNA polymorphisms (rs2151280, rs7763881, rs1136410, and rs3787016) on glioma risk and prognosis: A case‐control study

Deng

Zhou

et al. 2019

Molecular Carcinogenesis

View full text Add to dashboard Cite

Long noncoding RNA (lncRNA) polymorphisms are reportedly in connection with tumor susceptibility and prognosis. Glioma is one of the most aggressive and common cancers of the central nervous system. This study aimed to investigate the relationship between four lncRNA variants and glioma susceptibility and prognosis in a Chinese Han population. Sequenom Mass‐ARRAY was used to genotype 605 patients with glioma and 1300 cancer‐free individuals. Odds ratios or hazard ratios and related 95% confidence intervals were calculated to estimate the correlations. Logistic and Cox regression models, log‐rank tests, and Kaplan‐Meier curves were used for the statistical analysis. Six inheritance models showed that ANRIL rs2151280 variant genotype (A>G) was related to the susceptibility of glioma, while the other three lncRNAs showed no association. Patients treated with temozolomide or nimustine had better progression‐free survival (PFS) and overall survival (OS) than those treated with platinum. Besides, patients aged older than 40 years showed a poorer OS. The Cox multivariate analysis revealed that the rs1136410 GG genotype (A>G) was beneficial for OS and PFS. The Kaplan‐Meier analyses indicated that rs1136410 A>G and the rs7763881 A>C were associated with longer OS. ANRIL rs2151280 variant genotype might increase susceptibility of glioma. In addition, PARP1 rs1136410 variant genotype could be beneficial for the overall survival of patients with glioma. More research data are needed to further validate our results.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Impact of four lncRNA polymorphisms (rs2151280, rs7763881, rs1136410, and rs3787016) on glioma risk and prognosis: A case‐control study

Deng

Zhou

et al. 2019

Molecular Carcinogenesis

View full text Add to dashboard Cite

show abstract

“…Glioblastoma arises from glial cells in the brain (Ostrom, Gittleman, Stetson, Virk, & Barnholtz‐Sloan, ). Bepridil was previously applied by Johnson & Johnson Pharmaceutical Research for the treatment of angina and hypertension.…”

Section: Resultsmentioning

confidence: 99%

“…Glioblastoma is the most common type of glioma that arises from glial cells in the brain or spinal cord. The annual incidence rate of glioblastoma in adults is between 0.6 and 3.7 per 100,000 persons (Ostrom et al, ). Patients with glioblastoma usually have a mean survival rate of 3–4 months if without treatment (Krex et al, ; Rao, ).…”

Section: Discussionmentioning

confidence: 99%

Blockade of the forward Na⁺/Ca²⁺ exchanger suppresses the growth of glioblastoma cells through Ca²⁺‐mediated cell death

Wang

et al. 2019

British J Pharmacology

View full text Add to dashboard Cite

Background and PurposeThe Na+/Ca2+ exchanger (NCX) working in either forward or reverse mode participates in maintaining intracellular Ca2+ ([Ca2+]i) homeostasis, which is essential for determining cell fate. Previously, numerous blockers targeting reverse or forward NCX have been developed and studied in ischaemic tissue injury but barely examined in glioblastoma for the purpose of anti‐tumour therapy. We assessed the effect of NCX blockers on glioblastoma growth and whether NCX can become a therapeutic target.Experimental ApproachPatch‐clamp recording, Ca2+ imaging, flow cytometry, and Western blot were used to study the effects of specific and non‐specific NCX blockers on cultured glioblastoma cells. In vivo bioluminescent imaging was used to measure effects on grafted glioblastoma.Key ResultsSelectively blocking the reverse NCX with SEA0400, SN‐6, and YM‐244769 did not affect tumour cell viability. Blocking the forward NCX with bepridil, CB‐DMB, or KB‐R7943 elevated [Ca2+]i and killed glioblastoma cells. Bepridil and CB‐DMB caused Ca2+‐dependent cell cycle arrest together with apoptosis, which were all attenuated by a Ca2+ chelator BAPTA‐AM. Systemic administration of bepridil inhibited growth of brain‐grafted glioblastoma. Bepridil did not appear to have a cytotoxic effect on human astrocytes, which have higher functional expression of NCX than glioblastoma cells.Conclusions and ImplicationsLow expression of the NCX makes glioblastoma cells sensitive to disturbance of [Ca2+]i. Interventions designed to block the forward NCX can cause Ca2+‐mediated injury to glioblastoma thus having therapeutic potential. Bepridil could be a lead compound for developing new anti‐tumour drugs.

show abstract

“…Gliomas comprise the most common type of primary malignant brain tumor, and except for pilocytic astrocytoma and subependymal giant cell astrocytoma, nearly all are characterized by high recurrence rates, high mortality rates, and short survival times. 1 Of note, the 5-year survival rate of glioma patients postdiagnosis is only 5.5% whereas the median survival is approximate 14.5-16.6 months. These statistics indicate poor prognosis of this cancer despite availability of multiple treatments including surgery, radiotherapy and chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

<p>Rap2c as a Novel Biomarker for Predicting Poor Prognosis in Glioma</p>

Wang

Lin

et al. 2020

OTT

View full text Add to dashboard Cite

Rap2c is a member of the Ras superfamily that has been implicated in various types of cancers. However, its role in glioma remains elusive. This study aimed to elucidate the role of Rap2c in glioma and its specific molecular mechanism. Methods: We determined the expression of Rap2c in glioma tissues by Western blotting and immunohistochemistry (IHC) assays. The proliferation and apoptosis of cells were explored using CCK-8 and flow cytometry assay, whereas the migration and invasion of glioma cells were determined using transwell assay. The potential mechanism of Rap2c in the migration of glioma cell lines was investigated through Western blotting analysis and transwell assay. BALB/c nude mice were used to establish tumor models to test the effect of Rap2c on cancer metastasis in vivo. Results: Our data showed that the protein expression of Rap2c was significantly upregulated in glioma tissues compared with normal brain tissues, and Rap2c overexpression negatively correlated with 5-year overall survival rate. However, there was no correlation between Rap2c expression and clinicopathological parameters of glioma patients. Overexpression of Rap2c promoted the migration and invasion abilities of glioma cells but had no significant effect on the proliferation of glioma cells. Western blotting analysis revealed that Rap2c overexpression increased the phosphorylation level of extracellular signal-related kinase1/2 (ERK1/2), and this effect was abolished with U0126, a selective MEK inhibitor. Furthermore, overexpression of Rap2c induced lung metastasis of glioma cells in xenograft models. Conclusion: These findings indicate that high Rap2c expression predicts poor prognosis in glioma. Rap2c-mediated ERK1/2 phosphorylation initiates EMT cascade and promotes migration and invasion of glioma cells. Thus, targeting Rap2c and ERK signaling pathway could be a novel treatment modality for glioma.

show abstract

Epidemiology of Intracranial Gliomas

Cited by 90 publications

References 27 publications

Impact of four lncRNA polymorphisms (rs2151280, rs7763881, rs1136410, and rs3787016) on glioma risk and prognosis: A case‐control study

Impact of four lncRNA polymorphisms (rs2151280, rs7763881, rs1136410, and rs3787016) on glioma risk and prognosis: A case‐control study

Blockade of the forward Na⁺/Ca²⁺ exchanger suppresses the growth of glioblastoma cells through Ca²⁺‐mediated cell death

<p>Rap2c as a Novel Biomarker for Predicting Poor Prognosis in Glioma</p>

Contact Info

Product

Resources

About

Epidemiology of Intracranial Gliomas

Cited by 90 publications

References 27 publications

Impact of four lncRNA polymorphisms (rs2151280, rs7763881, rs1136410, and rs3787016) on glioma risk and prognosis: A case‐control study

Impact of four lncRNA polymorphisms (rs2151280, rs7763881, rs1136410, and rs3787016) on glioma risk and prognosis: A case‐control study

Blockade of the forward Na+/Ca2+ exchanger suppresses the growth of glioblastoma cells through Ca2+‐mediated cell death

<p>Rap2c as a Novel Biomarker for Predicting Poor Prognosis in Glioma</p>

Contact Info

Product

Resources

About

Blockade of the forward Na⁺/Ca²⁺ exchanger suppresses the growth of glioblastoma cells through Ca²⁺‐mediated cell death